Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
≥ 18 years if age
Diagnosed with stage III pancreatic cancer
Tumor is measurable
Glomerular Filtration Rate > 60 m/L/min/1.73 m(2)
Participating in another clinical trial for the treatment of cancer at time of screening
Are pregnant or currently breast feeding
Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure
Have non-removable implants with metal parts within 1 cm of the target lesion